Tritonix.ai

News / Korea / yonhap_finance

Shinhan Securities Advises Cautious Stance on Aesthetic Medical Device Stocks Ahead of Q3 Results

Health Technology · Medical Specialties · yonhap_finance · 2026-09-10

145020, 214450

Shinhan Securities recommends a conservative investment approach for aesthetic medical device stocks until Q3 earnings provide clearer market signals.

What Happened

Market Outlook: Shinhan Securities maintains an 'Overweight' rating on the aesthetic medical device sector, citing long-term growth potential, while advising a cautious approach until macroeconomic uncertainties subside and Q3 earnings are confirmed. Recent stock weakness is attributed to geopolitical risks and concerns over rising interest rates, which have dampened investor sentiment.

Company Analysis: Analysts highlighted that the fundamentals of key players remain intact, with PharmaResearch continuing high growth through channel expansion and Hugel entering a core growth phase following its U.S. direct sales launch. PharmaResearch was named the top pick, while Hugel was identified as a preferred stock.

Demand Trends: The rise of GLP-1 weight-loss drugs is creating secondary demand for aesthetic procedures to address facial volume loss and skin sagging. This trend suggests a significant expansion in the total addressable market for aesthetic treatments, providing a strong tailwind for Korean companies.

Strategic Investment: Increased interest from global players, such as Eli Lilly's venture capital arm exploring investments in the Korean aesthetic sector, underscores the industry's competitiveness. Investors are encouraged to focus on companies with clear visibility and growth prospects amidst the current volatile macroeconomic environment.

Read original

More in Health Technology

Kiwoom Securities: Interojo Poised for Revaluation Amid Beauty Lens Market Boom

Health Technology · yonhap_finance · 2026-09-10

Kiwoom Securities projects a valuation boost for Interojo, citing strong Japanese exports, retail expansion, and upcoming U.S. FDA product approvals.

119610

Rare Disease Families Face Regulatory Hurdles in Quest for Gene Therapy Access

Health Technology · cnbc · 2026-09-10

The struggle of the Stecker family to secure gene therapy for their son highlights the systemic challenges and ethical dilemmas in treating rare childhood diseases.

GILD

Tanvex BioPharma August Revenue Skyrockets 210% YoY

Health Technology · cnyes · 2026-09-10

Tanvex BioPharma (6541) reported a 210.14% year-over-year revenue surge for August 2026, with cumulative year-to-date growth reaching 250.13%.

6541

Latest in Korea

Elon Musk’s Boring Company Secures $3 Billion in Middle East-Led Funding

Industrial Services · yonhap_finance · 2026-09-11

The Boring Company has raised $3 billion in a Series D funding round, valuing the tunnel-boring startup at $23 billion as it eyes major expansion in the UAE.

Intel-Backed Altera Targets $2 Billion IPO to Fuel Market Return

Electronic Technology · yonhap_finance · 2026-09-11

Altera, the FPGA specialist partially owned by Intel, is preparing for a $2 billion IPO as part of Intel's broader efforts to restructure its finances.

KOSPI Slides Over 2% Amid Rising Oil Prices and Bond Yields

Electronic Technology · yonhap_finance · 2026-09-11

The KOSPI index fell over 2% to the 6,800 level as surging oil prices and rising U.S. Treasury yields weighed heavily on investor sentiment.

000660, 005930, 009150, 012450, 034020, 086520, 105560, 196170, 247540, 402340

US Diesel Prices Hit Record $6 Per Gallon Amid Supply Concerns

Energy Minerals · yonhap_finance · 2026-09-11

US diesel prices have surpassed $6 per gallon for the first time, fueling concerns over inflation and potential political fallout ahead of the midterms.